Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test

Reuters12-19

Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test

Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection (MCED) test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592751181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-19 05:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592751181","market":"nz","top_or_hot":-1,"title":"Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection (MCED) test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-19 05:16</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection (MCED) test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.</span></i>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0266013472.USD","symbol_name":"AXA WF - Framlington Longevity Economy A Cap USD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nNDLbLcWL8:1","article_id":"2592751181","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592751181","pubTimestamp":1766092609,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection  test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","EXAS":"精密科学","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4548":"巴美列捷福持仓","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"Exact Sciences在日本CRANE研究中招募了第一名参与者进行基于血液的癌症检测测试","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EXAS":0.9},"content_text":"Exact Sciences Enrolls First Participant in Japan CRANE Study for Blood-Based Cancer Detection Test\n    \n\n        Exact Sciences Corporation has announced the enrollment of the first participant in the CRANE Study, a multi-center case-control clinical evaluation in Japan. The study, conducted in collaboration with Japan's National Cancer Center Hospital East, will assess the clinical performance of Exact Sciences' blood-based Multi-Cancer Early Detection (MCED) test. The CRANE Study aims to enroll approximately 2,000 participants nationwide, including both individuals with and without cancer, to evaluate the test’s sensitivity and specificity across multiple cancer types and stages. The results of the study have not yet been presented and will be reported in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. EXACT Sciences Corporation published the original content used to generate this news brief on December 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592751181","isCrawlerRequest":true}